Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

REZLIDHIA

OLUTASIDENIB

Standard Dose
150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview REZLIDHIA is listed in Drugs@FDA under application 215814 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient OLUTASIDENIB Form and strength CAPSULE;ORAL - 150MG Sponsor RIGEL PHARMS Submission history Latest submission status date: 2022-12-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview REZLIDHIA is listed in Drugs@FDA under application 215814 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient OLUTASIDENIB Form and strength CAPSULE;ORAL - 150MG Sponsor RIGEL PHARMS Submission history Latest submission status date: 2022-12-01 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.